Clinical trial for Relapsed/Refractory Non-Hodgkin Lymphoma
Official title A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
ClinicalTrials.gov ID: NCT06090539
What this study is testing
What is BMS-986458?
This is an investigational medicine being studied to treat relapsed or refractory non-Hodgkin lymphoma. It is designed to target and break down a specific protein called BCL6 in the body.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study looks at how safe the drug is, how well it stays in the body, and whether it shows early signs of working against lymphoma.
- Who it's for
- It is for adults who have relapsed or refractory non‑Hodgkin lymphoma.
- What's involved
- Participants may receive the drug alone or with other lymphoma drugs, and will have regular visits for blood tests, scans and other safety checks.
- Time commitment
- The study lasts several months, with multiple clinic visits for treatment and monitoring.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants ≥ 18 years of age with frontline or R/R NHL.
- Participant must have measurable disease (defined by at least one FDG-avid lesion for FDG-avid disease and one bi-dimensionally measurable disease on...
- Participants must accept and follow pregnancy prevention plan.
You likely can't join if
- Participants must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.
- Participants with an inability to comply with listed restrictions, precautions and prohibited treatments.
- Participants must not have prior CAR-T, or radiotherapy ≤ 4 weeks, systemic anticancer treatment ≤ 5 half-lives or 4 weeks, allogeneic SCT ≤ 6 months...
- In BMS-986458 + T-cell engager combination cohorts: Participants must not have prior alloSCT or solid organ transplantation, history of confirmed...
- Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence...
- Participants must not have known or suspected central nervous system involvement.
See the full eligibility criteria
- Participants ≥ 18 years of age with frontline or R/R NHL.
- Participant must have measurable disease (defined by at least one FDG-avid lesion for FDG-avid disease and one bi-dimensionally measurable disease on cross sectional imaging by computed tomography or magnetic resonance...
- Participants must accept and follow pregnancy prevention plan.
- Participants must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.
- Participants with an inability to comply with listed restrictions, precautions and prohibited treatments.
- Participants must not have prior CAR-T, or radiotherapy ≤ 4 weeks, systemic anticancer treatment ≤ 5 half-lives or 4 weeks, allogeneic SCT ≤ 6 months (only applicable to BMS-986458 single agent or rituximab combination...
- In BMS-986458 + T-cell engager combination cohorts: Participants must not have prior alloSCT or solid organ transplantation, history of confirmed progressive multifocal leukoencephalopathy (PML)
- Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable...
- Participants must not have known or suspected central nervous system involvement.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Duarte, California, United States
- Tampa, Florida, United States
- Boston, Massachusetts, United States
- Rochester, Minnesota, United States
- New York, New York, United States
- Beijing, Beijing Municipality, China
- Guangzhou, Guangdong, China
- Nanchang, Jiangxi, China
- Bordeaux, Aquitaine, France
- Lille, Nord, France
- Villejuif, Paris, France
- Créteil, Val-de-Marne, France
- Montpellier, France
- Paris, France
- Toulouse, France
- Münster, North Rhine-Westphalia, Germany
- Homburg, Saarland, Germany
- Leipzig, Saxony, Germany
- Berlin, Germany
+ 15 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Duarte, California, United States; Tampa, Florida, United States; Boston, Massachusetts, United States; Rochester, Minnesota, United States; New York, New York, United States and 29 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.